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Sinusitis, acute otitis media and tonsillitis are very frequent 
in children. Most of these infections are caused by viruses, 
but are generally treated with antibiotics. Inappropriate use of 
antibiotics favors the selection, growth and spread of resistant 
bacteria; these bacteria colonize the airways and affect the 
entire community. With the emergence of antibiotic-resistant 
bacteria, respiratory infections have become more difficult 
to treat. Effective strategies are needed to restrict the use of 
antibiotics without harming children that truly need these 
drugs. Aim: to present a critical analysis of the results of 
randomized and controlled studies on clinical and laboratory 
criteria used in diagnosing and treating tonsillitis, sinusitis 
and otitis. Methods: a review of randomized and controlled 
studies about these conditions published in MEDLINE and 
SCIELO from 2000 to 2006. Conclusions: Given that most of 
these infections progress favorably without antibiotics, the use 
of these drugs should be avoided unless the child belongs to 
a high risk group for complications, or symptoms persist or 
worsen with despite symptomatic treatment. Physicians and 
laypersons should have better knowledge about the natural 
evolution of acute respiratory infections. 
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INTRODUCTION
The emergence of resistant microorganisms against 
antibiotics is directly related with the excessive use of 
these drugs.1-3 Upper airway infections are very common 
in children; nursing babies may present up to 10 or 12 
upper airway infections each year.4-6
Most cases of sinusitis, acute otitis media and ton-
sillitis are caused by viruses and their course is self-limited; 
however, it is common to see antibiotics used for treating 
these infections, especially in three situations: patients 
complaining of throat pain, children with hyperemic tym-
panic membranes or coughing with exudate, and sinus 
radiographs showing opacity. Lack of knowledge about 
the natural progression of upper airway infections, poor 
validation of the clinical history, the physical examination 
and epidemiological data are associated with the excessive 
use of antibiotics. There are also other equally important 
factors that lead to the abusive use of medication, such as 
the low predictive value of clinical signs to differentiate 
viral from bacterial tonsillitis, the absence of easy and 
low cost laboratory tests for diagnosing upper airway 
infections etiologically, difficulty in accessing medical 
services (which generates insecurity about the risk of com-
plications), false expectations that antibiotics used in viral 
upper airway infections will avoid future complications, 
and difficulties in interpreting radiological exams, which 
may not help differentiate viral sinusitis from bacterial or 
allergic sinusitis.4,5
In this review, the authors critically analyze the re-
sults of randomized and controlled studies about clinical 
and laboratorial criteria that are used for the diagnosis 
and treatment of tonsillitis, sinusitis and acute otitis media, 
based on the PUBMED and SCIELO databases.
TONSILLITIS
Tonsillitis may be caused by a variety of microor-
ganisms (Table 1); Group A beta-hemolytic streptococcus 
(or Group A Streptococcus pyogenes - GAS) is, however, 
the most common etiological agent. It may lead to suppu-
rative complications and non-suppurative conditions such 
as rheumatic fever and acute glomerulonephritis. It has 
been estimated that 75% of tonsillitis cases in children aged 
from 2 to 10 years are caused by viruses; however, most 
of these cases are treated with antibiotics.4-6 Excessive use 
of antibiotics in the treatment of pharyngotonsillitis maybe 
due to the difficulty in differentiating viral tonsillitis from 
those caused by Group A beta-hemolytic streptococcus 
(GABHS) and the expectation that antibiotics may avoid 
complications such as rheumatic fever.4-7
A meta-analysis comprising 27 studies totaling 
2,835 patients with throat pain revealed that antibiotic 
treatment reduced the risk of rheumatic fever by nearly 
80% (RR 0.22; 95% CI 0.02 to 2.08) and was associated 
with a lower risk of glomerulonephritis. There were also 
fewer suppurative complications: acute otitis media (RR 
0.30; 95% CI 0.15 to 0.58); acute sinusitis (RR 0.48; 95% 
CI 0.08 to 2.76); peritonsillary abscess (RR 0.15; 95% CI 
0.05 to 0.47). A decrease in symptoms (pain and fever) 
was seen only after the third day in the antibiotic-treated 
group, when about half of the placebo-treated patients 
were already asymptomatic. After one week, 90% of pa-
tients treated or not with antibiotics were symptom-free; 
for each six patients treated with antibiotics only one had 
a decrease in symptoms by the third day of treatment. The 
impact of antibiotics on symptoms was more significant 
when only patients with positive oropharyngeal swabs for 
streptococci were analyzed.7
Table 1. Main causal agents in acute tonsillitis.
Virus Bacteria    Others
Rhinovirus    
Streptococcus pyogenes Group A beta he-
molytic streptococcus)
Mycoplasma pneumoniae
Coronavirus    Groups C and G streptococcus Chlamydias  
Adenovirus  * Anaerobes      
Herpes virus types 1 and 2 Neisseria gonorrheae  
Parainfluenza virus Corynebacterium diphtheriae  
Coxackievirus  A Arcanobacter hemolyticum  
Epstein Bar Virus ** Yersinias  
Citomegalovirus            
HIV   
Infuenza A and B            
Note: * more common in children aged below 3 years; ** more common after age 3 years
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The main purpose of treating acute tonsillitis cases 
with antibiotics is to reduce the possibility of suppurative 
and non-suppurative complications associated with GA-
BHS, and to decrease the transmission of this bacterium to 
the community. Although there are many clinical criteria for 
differentiating bacterial and viral tonsillitis (Table 2), their 
sensitivity for identifying bacterial tonsillitis remains low.
for the antigen-detecting rapid strep test; for the positive 
clinical assessment, the sensitivity was 36%, the specificity 
was 97%, the positive predictive value was 83% and the 
negative predictive value was 77%.10
The prevalence of GABHS was 34% in a study done 
in Sao Paulo, which aimed to compare cultures, molecular 
hybridization and the rapid strep test for detecting the 
GABHS-antigen in 50 children aged from 1 to 12 years 
with acute pharyngotonsillitis. GABHS was found in 30% 
of cultures, in 25% of the samples tested with molecular 
hybridization, and in 26% of the fast antigen detection 
test; there was no statistically significant difference among 
these three methods.11
Another study of 81 subjects aged over 12 years 
found that the rapid strep test sensitivity and specificity 
were 93.9% and 68.7%, and that the negative and positive 
predictive values were 94.2 and 67.4%.12
Although tonsillary cultures are considered the 
gold standard for the final etiological diagnosis of GABHS 
tonsillitis (about 95% accuracy), this test is not easily avai-
lable and its results are slow. The American Academy of 
Pediatrics recommends using fast detection diagnostic tests 
for the specific group of streptococcal carbohydrates (en-
zyme immunoassay and latex agglutination) to differentiate 
viral from bacterial tonsillitis; these tests provide prompt 
results and are sensitive and specific for the diagnosis of 
streptococcal tonsillitis. It is important to note that neither 
oropharyngeal cultures nor rapid strep tests for detecting 
streptococci are able to differentiate patients with disease 
from GABHS carriers.5,13
In developed countries, rapid strep tests for de-
tecting oropharyngeal streptococcal antigens are being 
used more and more, given their high sensitivity. In Bra-
zil, although these test have been used in some private 
clinics, they are not available in most public health units; 
the diagnosis is thus still based only on clinical criteria. 
Since these criteria are not sensitive for detecting GABHS 
tonsillitis, and given the risk of rheumatic fever in develo-
ping countries, the aforementioned tests should be made 
available so that clinicians working in public healthcare 
may avoid using antimicrobials excessively.4-7
Prompt treatment of GABHS is not essential for 
preventing rheumatic fever, since the incidence of this 
complication is low when therapy is initiated up to nine 
days following the onset of symptoms. Although there 
are few benefits in avoiding the symptoms of tonsillitis, 
early therapy drastically reduces the transmission of strains 
causing rheumatic fever or acute glomerulonephritis. The 
risk of GABHS transmission in closed environments (hou-
seholds or schools) is high (35%); this risk fall markedly 
within 24 hours of penicillin therapy. On the other hand, 
early treatment of streptococcal infection is associated with 
a lower serological response and an increased recurrence 
rate of this infection.13
Table 2. Clinical features of bacterial tonsillitis.
-Age between 5 and 15 yearss
- High fever
- Intense inflammation of the pharynx and tonsils: pain, edema, 
and exudate
- Presence of painful and enlarged anterior cervical lymph nodes 
(> 1.0 cm)
- Absence of signs and symptoms suggesting a viral cause: con-
junctivitis, hoarseness, diarrhea and coryza
- History of exposure to a patient with streptococcal disease or 
onset of condition at the end of winter and beginning of spring
In the Netherlands 156 children (aged 4 to 15 years) 
with at least two criteria suggesting bacterial infection and 
a complaint of throat pain for at least seven days were 
evaluated, and the effectiveness of three or seven days 
of penicillin therapy was assessed. Use of the antibiotic 
did not decrease the symptoms or the complication rate, 
regardless of whether the children had confirmed or un-
confirmed GABHS infection. However, in 96 children (60%) 
that had positive oropharyngeal cultures for GABHS and 
that were not treated with antibiotics, there was a higher 
recurrence rate of tonsillitis. It may be possible that the 
low complication detection rate was associated with the 
small sample size and a low prevalence in that country 
of nephrogenic strains or those associated with rheumatic 
fever. Thus, an inadequate diagnosis and treatment of 
streptococcal tonsillitis may increase the risk in regions 
where there is a high prevalence of rheumatic fever.8
A study comprising 1,810 children in three countries 
was undertaken to assess the World Health Organization 
criteria for identifying children with GABHS tonsillitis; this 
study revealed that the percentage of GABHS tonsillitis 
ranged from 25.6% in Brazil to 42% in Croatia. Although 
the World Health Organization criteria were highly specific 
for this bacterium (94 to 97%), the sensitivity was lower 
than 12%. These authors concluded that more sensitive 
criteria are needed for identifying GABHS, especially in 
places where the incidence of rheumatic fever is high.9
In Sweden, the GABHS was found in oropharyngeal 
cultures in 53 of 169 (31%) children aged over 4 years with 
acute tonsillitis. Among children with all of the highly sug-
gestive criteria for bacterial infection (24%), the sensitivity 
was 82%, the specificity was 96%, the positive predictive 
value was 90% and the negative predictive value was 93% 
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Treating GABHS tonsillitis adequately is just as 
important as diagnosing this condition correctly. Unfortu-
nately, this is not what occurs in practice. Many children 
with throat pain are given inappropriate antibiotics for 
eradicating GABHS from the oropharynx, or are treated 
in shorter than recommended periods or incorrect doses 
or dose intervals.5,6,13
Various antibiotics are able to eradicate GABHS; 
some of them may be given in shorter regimens and in 
single daily doses, which may increase compliance. Ho-
wever, S. pyogenes remains highly sensitive to penicillin 
and cephalosporins.13-16
Although macrolides may facilitate the treatment of 
streptococcal infections, low-dose azithromycin regimens 
appear to be inadequate for treating GABHS tonsillitis; 
furthermore, macrolide resistance is directly associated 
with its use. It is advisable to restrict the use of these dru-
gs to patients that are allergic to penicillin or that present 
recurring tonsillitis.13
A metanalysis of 19 studies comprising 4,626 pa-
tients showed that treatment with 60 mg/kg azithromycin 
was superior to 10 days of treatment with penicillin or 
cephalosporins. Failures in eradicating GABHS were five 
times more frequent with other antibiotics compared to 
azithromycin; but when azithromycin was given at a dose 
of 30 mg/kg per treatment, its effectiveness was three ti-
mes lower compared with a ten day treatment with other 
antibiotics. A treatment of tonsillitis with azithromycin, at a 
dose of 60 mg/kg in children or 500 mg/day during three 
days in adults is superior to therapy with other antibiotics, 
such as penicillin or the cephalosporins; it also has the 
advantage of reducing compliance problems.14
Studies done in the USA and Europe have shown 
that cephalosporins are three to four times more effective 
than oral penicillin for eradicating S. pyogenes as de-
monstrated in the laboratory.15 A metanalysis comprising 
47 studies with 11,426 patients compared cephalosporins 
during 10 days against penicillin during 10 days and de-
monstrated that in Europe the bacteriological failure rate 
with cephalosporins was 4.3 times lower, and in the USA 
the same failure rate was 2.7 times lower. Studies that 
compared short cephalosporin treatments (4 to 5 days) 
with the classical oral penicillin treatment for 10 days also 
showed lower bacteriological failure rates with cephalos-
porins, although decreases in the failure rate were lower 
than that seen when cephalosporins were given for 10 
days (1.3 to 2.4).16
A study done in teenagers and adults with GABHS-
cause tonsillitis revealed that clindamycin at a dose of 
300mg BID was equally effective compared to the asso-
ciation amoxicillin/clavulanate.17
Although these results have shown that some of 
the recent antibiotics are equally or more effective than 
penicillin in the treatment of GABHS tonsillitis, it should 
be borne in mind that these drugs are more costly, and 
that cephalosporins and macrolides have a higher impact 
on the selection of resistant strains compared to betalac-
tamic drugs.18
Betalactamic antibiotics remain the first choice of 
treatment for bacterial tonsillitis, given their lower cost 
and a lower prevalence of resistant S. pyogenes against 
these drugs.13,19-21
Finally, it is important to underline the need for 
caution when using non-steroidal anti-inflammatory drugs 
in the treatment of children with fever; if symptoms remain, 
other causes should be sought, such as viral infection or 
atypical bacteria.22,23
SINUSITIS
The common cold is the most frequent infectious 
disease in children and adults; it often causes persistent 
nasal exudate over more than seven to ten days. The nasal 
mucosa is continuous with the paranasal cavities; viral in-
fections may thus also lead to sinus disease. Acute bacterial 
sinusitis, which is one of the most frequent complications 
of the common cold, should always be suspected in chil-
dren with coughing and purulent nasal exudate lasting 
more than 10 to 14 days or when fever persists or recurs 
after the fourth day of an upper airway infection.
Plain radiographs of the paranasal cavities are not 
useful for the diagnosis of acute bacterial sinusitis, since 
both the common cold and allergic conditions may cause 
paranasal cavity opacity on radiographs, which cannot 
be distinguished from the radiological findings of acute 
bacterial sinusitis. When acute bacterial sinusitis is suspec-
ted or when symptoms recur, the best exam is computed 
tomography.2-6
Although many children with coughing and persis-
tent nasal exudate are treated with antibiotics, these drugs 
are often little effective in solving the problem. Some 
studies have shown that symptoms resolve in only one of 
eight treated children (95% IC - 5 to 29).24,25
A recent randomized controlled study comprising 
82 children with nasal symptoms and image exams (ul-
trasound and paranasal radiographs) suggesting sinusitis 
revealed that the efficacy of therapy with cefuroxime 
axetil (125mg, BID, 10 days) was similar to the placebo; 
no significant difference was found in the proportion of 
completely cured children after two weeks. Cefuroxemine 
reduced the symptoms in only 6% of cases (95% IC -16 
to 29).26
As with tonsillitis, the choice of the best therapy re-
gimen for children with suspected bacterial sinusitis varies 
in different places; while some recommend amoxicillin 
in usual dosages, other advocate using wide spectrum 
antibiotics, such as high dose amoxicillin and clavulanate, 
cephalosporins and macrolides.
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An analysis of 33 studies revealed that clarithromy-
cin, compared to amoxicillin and amoxicillin/clavulanate, 
had little added benefit in reducing the symptoms of rhino-
sinusitis (OR = 1.12). Although clarithromycin is effective 
and safe for treating rhinosinusitis, its higher cost compared 
to betalactamic antibiotics has to be taken into account. 
The same applies to hew drugs such as telithromycin, 
which has been shown to be effective in adults at a dose 
of 800mg, once a day, for five days.27-29
Other recommended treatments for acute sinusi-
tis include hypertonic saline solution and topical nasal 
corticosteroids. Most of the studies that compared these 
approaches with antibiotics or placebo have been done 
in selected adult groups1,2,5,30,31
ACUTE OTITIS MEDIA
Acute otitis media is one of the most common in-
fections in infancy, and the main reason given for using 
antibiotics in children; almost all children have had at 
least one episode of acute otitis media by age 3 years. 
Of these, 20% will present multiple episodes. It has been 
estimated that about 80% of acute otitis media episodes 
in nursing babies are cased by bacteria, in particular three 
organisms: S. pneumoniae, non-typifiable H. influenzae 
and M. catarrhalis32,33.
Amoxicillin has been considered the drug of choice 
for treating acute otitis media, based on pharmacokinetic 
and pharmacodynamic principles; it has an adequate 
spectrum, excellent penetration into the middle ear, low 
toxicity and low cost. However, due to the many cases of 
acute otitis media that resolve spontaneously, as well as 
concerns about the excessive use of antibiotics, in many 
regions the recommendation is not to treat acute otitis 
media with antibiotics unless children present high fever or 
persistent signs and symptoms after being given analgesic 
for 48 to 72 hours.32-36
In the Netherlands, only 31% of children with acute 
otitis media are given antibiotics, while in the USA and 
Australia this rate is over 95%.33
A metanalysis of eight studies comprising 2,287 
children with acute otitis media found that antibiotics were 
not superior to placebo in relieving symptoms within the 
first 24 hours of treatment, but reduced pain in 30% of 
cases after two to seven days.33 As the clinical condition 
resolved spontaneously in 80% of untreated children, the 
estimated benefit of antibiotic use was only 7%; estimates 
showed that symptoms resolved in only one child out of 
15 that were treated with antibiotics.33
Symptoms of acute otitis media resolve in 61% of 
children after 24 hours, and in 80% after two to three 
days,36 regardless of antibiotic treatment. 
One of the most significant issues when assessing 
children with otalgia is to differentiate acute otitis media 
from otitis media with effusion, due to a lower complica-
tion rate. The diagnosis of acute otitis media is based on an 
abrupt onset of otalgia and fever with fluid in the middle 
ear (tympanic membrane bulging, decreased or absent 
tympanic membrane mobility, fluid level behind the tym-
panic membrane or acute otorrhea) and an erythematous 
membrane. The differential diagnosis between acute otitis 
media and otitis media with effusion is not always easy, 
especially when the physical exam is done of a feverish, 
irritable and crying child with an upper airway infection, 
since crying is also associated with tympanic membrane 
erythema.5,6
Added to these concerns about the immediate con-
sequences of acute otitis media (complications and recur-
rence), doubts persist about whether antibiotics affect the 
resolution of the middle ear effusion or if lack of treatment 
affects hearing. Most of the children presenting otitis media 
with effusion after acute otitis media progress well.37,38
It has been estimated that 59% of middle ear effu-
sions following an episode of acute otitis media resolve 
within one month, and 74% of these cases resolve within 
three months. In cases of otitis media with effusion of 
unknown duration, resolution is 28% after 3 months and 
42% after 6 months; in cases of chronic otitis media with 
effusion, resolution is somewhat slower (26% after 6 mon-
ths and 33% after 12 months).37
A recently published randomized study about the 
progression of acute otitis media revealed that resolution 
of the middle ear effusion in children with acute otitis 
media occurs, on average, 7.5 days after treatment with 
amoxicillin or cefuroxime axetil is started, and that the 
conditions resolves in 69% of children after 14 days. The 
effusion in children with unilateral acute otitis media re-
solves more rapidly (5 days) than in children with bilateral 
effusion (10 days), and that bilateralism of acute otitis 
media was strongly associated with an increased risk of 
failure of therapy after two weeks, regardless of which 
antibiotic was used.38
The results of a Canadian study designed to com-
pare the effectiveness of amoxicillin (60 mg/kg/day) with 
placebo in children with acute otitis media revealed that 
the response was 92.8% after 14 days of antibiotic treat-
ment, and 84.2% in the placebo group. Amoxicillin therapy 
was superior to placebo, but the effect was small (8.6%). 
Most of these children progress well without antibiotics; 
the frequency of pain and fever during the first two days 
in the antibiotic-treated group was lower.
Recently published studies have recommended a 
more careful approach in the treatment of acute otitis 
media (WASP - wait and see prescription approach).32-40
In another study, children aged from 6 months to 
12 years with mild or moderate acute otitis media were 
randomized for prompt antibiotic treatment (n=112) or 
antibiotics only if symptoms persisted (n = 111). Family 
members and caretakers accepted well this type of gui-
dance, and on day 12, 69% of antibiotic-treated children 
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had normal tympanic membranes compared to 51% in the 
control group. Tympanometry was within normal limits in 
25% of children in the antibiotic-treated group and in 10% 
of children in the control group. There were 16% fewer 
failures in children treated promptly with antibiotics, but 
66% of children in the control group did not require anti-
biotics; the cost in the antibiotic-treated group was US$47 
on average, against US$11 on average in the control group. 
Visits to the emergency room, school or work absenteeism 
and recurrences were identical in both groups. The au-
thors concluded that the instruction of using antibiotics 
only if symptoms persisted, compared to prompt antibiotic 
use, reduced antibiotic use by 73%. Furthermore, prompt 
antibiotic use increased oropharyngeal colonization by 
multiresistant S. pneumoniae strains soon after cessation 
of treatment.34
Still another study comprised 283 children with 
acute otitis media (6 months to 12 years) randomized 
either to be given antibiotics only if symptoms persisted 
or worsened not relieved by ibuprofen (WASP approach) 
or to the classical approach of prompt antibiotic and anal-
gesic therapy. The results revealed that 63% of children 
did not require antibiotics and had no complications in 
the WASP approach group. Medication use was associated 
with persistent fever or otalgia.39
Little et al. (2006)40 monitored 315 children aged 
from 6 months to 10 years during one year, which had 
been randomized into a prompt antibiotic therapy group 
and a conservative approach group (WASP, or giving 
antibiotics only if symptoms persisted or worsened re-
gardless of analgesics) for the treatment of acute otitis 
media. The short-term, 3-month and 12-month progression 
was similar in both groups, except for children with two 
or more previous episodes of acute otitis media. Among 
these children there were more recurrences of otalgia in 
the first three months (39% vs. 10%), but the number of 
sequelae one year later was not different from the groups 
of children treated with antibiotics. These data suggest that 
prompt antibiotic therapy does not alter the progression 
of acute otitis media.40
The American Academy of Pediatrics (Table 3) re-
commends prompt antibiotic treatment in the following 
conditions:
1) children aged below six months;
2) children aged from 6 to 24 months with evident 
signs of acute otitis media, high fever and/or intense otal-
gia, or if the child cannot be reassessed if the condition 
worsens;
3) children with an underlying disease (immuno-
compromised, with cleft palate, malformed);
4) children aged over 2 years whose symptoms do 
not regress after 48 to 72 hours of symptomatic therapy.
Although many studies have shown that most 
children with otitis, not treated with antibiotics, improve 
rapidly and have no complications, criticism has been 
leveled at the more conservative approach: 
1) inclusion and exclusion criteria in these studies 
are not always clear; 
2) many studies have included few children aged 
under 2 years, exactly those more prone to complica-
tions; 
3) not all children seek medical help within the first 
24 hours of the onset of symptoms; it is not advisable to 
wait another 48 to 72 hours before starting antibiotics in 
symptomatic children; 
4) it is not always possible to assure that children 
will return for a reevaluation, especially in emergency 
care units; 
5) some studies have indicated that suppurative 
complications, such as mastoiditis, are more frequent in 
countries with more restrictions against using antibiotics for 
the treatment of acute otitis media; since this complication 
is rare, the sample size needs to be larger to assure that 
there are no differences in the progression of children with 
acute otitis media treated or not with antibiotics.40-43
Table 3. Recommendations for using antibiotics in acute otitis me-
dia.
1.
Children under age 6 months, even if symptoms are not se-
vere and fever is not high, due to the high complication risk;
2.
Children aged from 6 to 24 months with high fever (T≥ 390C 
within the last 24 hours) or severe otalgia or if a reassess-
ment is not possible if the condition worsens;
3.
Children over age 24 months with fever and/or intense 
otalgia or if the condition persists or worsens after 48 to 72 
hours of symptomatic therapy;
4.
Children with predisposing diseases for acute otitis media 
(cleft palate, genetic syndromes, immune deficiency).
Antibiotic selection for treating acute otitis media is 
also controversial. While some authors have recommended 
therapy with high doses of amoxicillin (80 to 90 mg/kg/
day), other authors have suggested that the usual doses (40 
to 45 mg/kg/day) are enough for treating children living 
in communities in which the prevalence of penicillin-
resistant S. pneumonia is low as well as in children over 
6 months that have been given at least three doses of the 
heptavalent pneumococcal conjugated vaccine. In areas 
where the prevalence of antibiotic-resistant strains is high, 
use of wide-spectrum antibiotics, such as cephalosporins 
and macrolides, is becoming more and more common. 
Dosages and duration of treatment also vary; some studies 
have indicated that cephalosporins or azithromycin during 
3 to 5 days may be as effective as 10 days of amoxicillin, 
with a higher probability of adhesion to the treatment.13,44-47 
Many of these recommendations have been based on stu-
dies that used double tympanocentesis to assess whether 
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the bacteria had been eradicated from the middle ear; 
furthermore, these studies have taken place in countries 
where the prevalence of bacterial resistance is high.
Unfortunately, the local patterns of antibiotic resis-
tance of strains that colonize the airways of children remain 
unknown in most areas, making it difficult to select the 
best antibiotic regimen for treating acute otitis media. It is 
essential to bear in mind that all antibiotics may increase 
resistance when deciding upon their use; furthermore, 
wide-spectrum antibiotics, such as the macrolides and new 
cephalosporins, have a higher ecological impact and are 
more costly than amoxicillin.18
For these reasons, we believe that the best approach 
in the treatment of acute otitis media is to restrict antibiotic 
use in mild acute otitis media cases (low fever and little 
pain) as long as the child may be reassessed in the short-
term if symptoms worsen or persist, and if necessary to 
initiate therapy with amoxicillin at usual doses. Exceptions 
would be children at risk for resistant infections (recent an-
tibiotic treatment, recurring otitis, immune deficiency).
The use of other drugs to treat acute otitis media, 
such as decongestants, non-steroidal anti-inflammatory 
drugs, and topical nasal or oral corticosteroids, is also 
controversial. Most of these drugs appear to provide no 
benefit to children with acute otitis media, and may cause 
adverse events.48-49 Although topical corticosteroids singly 
or with antibiotics may have some effect in reducing mi-
ddle era effusions in the short term, there is not enough 
information to assess their long-term efficacy; they should 
thus be recommended only for children with signs and 
symptoms of atopic disease.50
CONCLUSION
The clinical history, the physical exam, and epide-
miological data are essential for the diagnosis of tonsillitis, 
sinusitis and otitis.
Rapid strep tests for detecting streptococcal antigens 
in the oropharynx should be made available in public 
and private healthcare units, given the poor specificity 
of clinical criteria for differentiating between viral and 
bacterial tonsillitis.
Most cases of acute bacterial sinusitis and acute otitis 
media progress favorably without antibiotics; the guideli-
ne of prescribing analgesics/antithermic medication and 
nasal hygiene should be the first measure in the treatment 
of these infections. This approach is only applicable to 
children aged over 6 months, with no co-morbidities or 
signs and symptoms of severe disease.
Physicians and lay persons need to be informed 
about the natural progression of upper airway infections 
and the risks of excess antibiotic use in children; at the 
same time, these children need to have prompt access to 
a reassessment if symptoms persist or worsen. In these 
situations, antibiotic treatment should be started imme-
diately.
A surveillance system providing information about 
resistant patterns of S. pneumoniae and H. influenzae 
strains that colonize the airways and that cause acute otitis 
media in children is needed, since there are wide local and 
seasonal variations in the resistance to antibiotics.
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